Quantification of natural growth of two strains of Mycobacterium marinum for translational anti‐tuberculosis drug development by Wijk, R.C. van et al.
Citation: Clin Transl Sci (2020) 13, 1060–1064; doi:10.1111/cts.12793
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Quantification of Natural Growth of Two Strains 
of Mycobacterium Marinum for Translational 
Antituberculosis Drug Development
Rob C. Van Wijk1, Astrid M. van der Sar2, Elke H.J. Krekels1, Theo Verboom2, Herman P. Spaink3, Ulrika S.H. Simonsson4,*,† and 
Piet H. van der Graaf1,5,*,†
The zebrafish infected with Mycobacterium marinum (M. marinum) is an attractive tuberculosis disease model, showing 
similar pathogenesis to Mycobacterium tuberculosis (M. tuberculosis) infections in humans. To translate pharmacological 
findings from this disease model to higher vertebrates, a quantitative understanding of the natural growth of M. marinum 
in comparison to the natural growth of M. tuberculosis is essential. Here, the natural growth of two strains of M. marinum, 
E11 and MUSA, is studied over an extended period using an established model-based approach, the multistate tuberculosis 
pharmacometric (MTP) model, for comparison to that of M. tuberculosis. Poikilotherm-derived strain E11 and human-derived 
strain MUSA were grown undisturbed up to 221 days and viability of cultures (colony forming unit (CFU)/mL) was determined 
by plating at different time points. Nonlinear mixed effects modeling using the MTP model quantified the bacterial growth, 
the transfer among fast, slow, and non-multiplying states, and the inoculi. Both strains showed initial logistic growth, reach-
ing a maximum after 20–25 days for E11 and MUSA, respectively, followed by a decrease to a new plateau. Natural growth 
of both E11 and MUSA was best described with Gompertz growth functions. For E11, the inoculum was best described in the 
slow-multiplying state, for MUSA in the fast-multiplying state. Natural growth of E11 was most similar to that of M. tuberculo-
sis, whereas MUSA showed more aggressive growth behavior. Characterization of natural growth of M. marinum and quantita-
tive comparison with M. tuberculosis brings the zebrafish tuberculosis disease model closer to the quantitative translational 
pipeline of antituberculosis drug development.
The zebrafish (Danio rerio) is an increasingly utilized disease 
model organism to study tuberculosis.1,2 Infections of zebrafish 
embryos with Mycobacterium marinum (M. marinum), a close 
relative of Mycobacterium tuberculosis (M.  tuberculosis),3 
show similar pathogenesis to M. tuberculosis infection in hu-
mans.4 The zebrafish as a disease model organism has several 
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE  
TOPIC?
✔  Zebrafish infected with Mycobacterium marinum 
(M.  marinum), a close relative to Mycobacterium tuber-
culosis (M.  tuberculosis), show similar pathogenesis to 
M.  tuberculosis infections in humans, making this a fre-
quently used disease model to study tuberculosis pathol-
ogy and antituberculosis pharmacology.
WHAT QUESTION DID THIS STUDY ADDRESS?
✔  The natural growth of two M.  marinum strains (E11 
and MUSA) is characterized over a period of > 200 days 
and quantitatively compared with the natural growth of 
M. tuberculosis.
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
✔  The poikilotherm-derived strain (E11) showed most sim-
ilar growth parameters and behavior to those of M. tuber-
culosis. The human-derived strain (MUSA) showed more 
aggressive growth. This suggests that studies with E11 are 
more predictive of antibiotic effects on M. tuberculosis.
HOW MIGHT THIS CHANGE CLINICAL PHARMACOL-
OGY OR TRANSLATIONAL SCIENCE?
✔  Quantitative knowledge on the similarities and differ-
ences in natural growth between M. marinum strains and 
M. tuberculosis is essential for the translation of pharma-
cological findings on antituberculosis drugs between the 
zebrafish and higher vertebrates, including humans.
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advantages. In contrast to experiments in higher vertebrates, 
like rodents, experiments with the zebrafish and specifically 
the zebrafish embryos and larvae are less time-consuming 
and resource-consuming. This is because of their high fecun-
dity, small size enabling experiments in microtiter plates with 
high throughput potential, ease of noninvasive imaging due to 
its transparency, and limited ethical constraints.5–7 As a whole 
vertebrate organism, it contains all relevant organ systems, 
including the immune response, which is an advantage over in 
vitro experiments. In tuberculosis research, this is especially 
relevant, as it has been shown that M. tuberculosis responds 
differently to treatment intracellularly inside macrophages, in 
comparison to standard (extracellular) in vitro experiments 
without macrophages.8,9 Moreover, the interaction among 
pathogen, immune response, and treatment might be more 
relevant to study in the zebrafish, as it shows granuloma for-
mation upon infection,10 which is not observed in the mouse, 
the standard preclinical organism in tuberculosis research.11 
Translation of pharmacological findings from zebrafish em-
bryos to higher vertebrates, including humans, requires a 
quantitative understanding of similarities and differences in 
pathophysiology between infecting mycobacteria. This forms 
the basis for a translational framework in drug development. 
One proposed model-based drug development approach 
for tuberculosis is the multistate tuberculosis pharmacom-
etric (MTP) model.12 This model distinguishes three states of 
multiplication for mycobacteria (i.e., fast, slow, and non-mul-
tiplying states) and characterizes growth rates and transfer 
rates among these states in the absence and in the presence 
of drugs, to better understand and translate drug effects. 
The MTP model has been successfully used in translation 
of pharmacological findings of M.  tuberculosis treatment in 
vitro,12 to mice13 and humans.14–18 To include the zebrafish in 
the translational pipeline for tuberculosis drug development, it 
is necessary to study the natural growth of M. marinum and 
quantitatively compare this to M. tuberculosis.
Here, the natural growth of M. marinum was studied over 
an extended period in two strains, one poikilotherm-derived 
(E11) and one human-derived (MUSA) strain. To facilitate a 
quantitative comparison to natural growth of M. tuberculosis 
and thereby assess the translational potential of pharmaco-
logical findings between species, the natural growth was 
characterized using the MTP model.12
METHODS
Total bacterial count assay
To replicate the experimental paradigm of the M. tuberculo-
sis natural growth,12 the two strains of M. marinum that are 
most commonly utilized in the zebrafish as a disease model 
are grown for an extended period of time in hypoxic condi-
tions. To remain hypoxic, individual culture tubes can only 
be used for a single time point, as opening the tube for sam-
pling introduces oxygen to the culture. M. marinum strains 
E1119 and MUSA20 were cultured in DifcoTM Middlebrook 
7H9 broth medium (BD Biosciences, Franklin Lakes, NJ) 
containing 0.05% Tween80 (Merck  KGaA, Darmstadt, 
Germany) and 10% BBLTM Middlebrook Albumin Dextrose 
Catalase Enrichment (BD Biosciences) at 30°C in closed 
tubes without disturbance up to 221 days. For each strain, 
three biological replicates from individually grown colonies 
were collected in individual tubes per time point, with a 
start inoculum at OD600 of 0.05, approximating 1× 10
6 CFU/
mL. At different time points (0, 8, 11, 18, 23, 28, 36, 42, 49, 
56, 64, 69, 77, 85, 92, 112, 114, and 221 days), the viability 
of the cultures, defined as CFUs per mL, was determined 
by plating a series of 10-fold dilutions (ranging from 1:10 to 
1:1,000,000) in triplicate on Difco Middlebrook 7H10 agar 
(BD Biosciences) containing 5% glycerol (Sigma-Aldrich, 
Saint Louis, MO) and 10% BBLTM Middlebrook Oleic 
Albumin Dextrose Catalase Enrichment (BD Biosciences).
Model-based quantification of natural growth
Nonlinear mixed effects modeling using the First Order 
Conditional Estimation was performed with NONMEM (ver-
sion 7.3)21 through interfaces Pirana (version 2.9.6) and PsN 
(version 4.7.0). Graphical outputs were generated with R 
(version 3.5.0) through interface Rstudio (version 1.1.383; 
RStudio, Boston, MA).
The previously developed MTP model12 for M. tuberculosis 
was used to fit the CFU/mL of both M. marinum strains. The 
model structure consisted of three bacterial states for fast, 
slow, and non-multiplying bacteria, where the sum of fast and 
slow-multiplying bacteria was assumed to equal CFUs/mL:
dF
dt
=kg ⋅F+kSF ⋅S−kFS ⋅F−kFN ⋅F
dS
dt
=kFS ⋅F+kNS ⋅N−kSF ⋅S−kSN ⋅S
dN
dt
=kFN ⋅F+kSN ⋅S−kNS ⋅N
in which F represented the fast-multiplying, S the slow-mul-
tiplying, and N the non-multiplying state, kg represents the 
growth function, and k-values represent transfer rates from 
the state first mentioned in the subscript to the state men-
tioned second. To ascertain mathematical identifiability, 
the transfer rates were fixed to values obtained in the MTP 
model for M. tuberculosis, with the exception of the trans-
fer rate between the fast and slow-multiplying state, which 
was estimated. Without fixing these parameters, the MTP 
model was not identifiable and, therefore, the translational 
potential of this study would be lost. By fixing the transfer 
rates to those found in M. tuberculosis, it was implicitly as-
sumed that the natural growth behavior as a result of the 
transfer between the different states was similar between 
M. tuberculosis and M. marinum. This was considered not 
biologically unreasonable, because both M.  tuberculosis 
and M. marinum share a genetic program for (intracellular) 
growth4 and genetic functions required for dormant infec-
tions are found in both genomes.22
To quantify the growth rate for the M. marinum strains, ex-
ponential, Gompertz, and logistic functions were tested, which 
assumed unrestricted (exponential) or restricted (Gompertz, lo-












Clinical and Translational Science
Natural Growth of M. marinum
Van Wijk et al.
where kg,e is the exponential growth rate, kg,G is the 
Gompertz growth rate, Bmax is the maximum capacity of 
the system, and kg,l is the logistic growth rate. The trans-
fer rates between the fast and slow-multiplying state 
were tested as a constant, or with capacity-dependent 
or time-dependent functions. Capacity-dependent trans-
fer was considered in case an excess total bacterium 
led to an increased transfer from the fast-multiplying 
to slow-multiplying state. For the time dependency, lin-
ear as well as sigmoidal and exponential functions were 
tested, as described previously.12 The inoculum at t  = 0 
was tested to either be all in the fast-multiplying state (F0), 
or all in the slow-multiplying state (S0), or both F0 and S0 
were estimated. This was based on the assumption that 
an in vitro infection starting from fresh cultures would 
consist of multiplying bacteria, either fast and/or slow. No 
bacteria were assumed to be non-multiplying at the logis-
tic growth phase at the start of the experiment, therefore, 
N0 was fixed to zero.
Two levels of variability were tested to distinguish bio-
logical from experimental variability. However, biological 
variability could not be estimated with acceptable precision. 
Residual error was quantified as a proportional error.
Model selection criteria were biological plausibility of 
parameter estimates, as well as standard goodness-of-fit 
plots.23 The likelihood ratio test was used to test statistical 
significance between nested models, where a drop in objec-
tive function value (∆OFV) of 3.84 corresponded to P = 0.05 
with a single degree of freedom, assuming the χ2-distri-
bution. Non-nested models were compared by Akaike 
Information Criterion (AIC), which penalizes ∆OFV with the 
number of additional parameters.24 Model diagnostics were 
performed by goodness-of-fit plots and a visual predictive 
check.23
RESULTS
Total bacterial count M. marinum
Both M.  marinum strains show an initial logistic growth 
phase as represented by the steep increase in CFU/mL in 
Figure 1a,b. This growth phase reaches a maximum for E11 
at 1 × 109 CFU/mL after 20 days, after which it decreases 
to a plateau of 1 × 107 CFU/mL after 100 days. For MUSA, an 
initial maximum was reached after 25 days at 3 × 108 CFU/
mL. Its decrease to a plateau similar to E11 was, however, 
less clear, due to high variability.
MTP model predictions of natural growth
For strain E11, the MTP model with a Gompertz growth 
function, constant transfer rates between the fast and 
slow-multiplying states, and the inoculum estimated to 
be exclusively in the slow-multiplying state, resulted in 
the best fit. Both a linear and logistic growth function 
decreased the fit substantially (∆AIC  =  40.8 and 39.2, 
respectively). Estimating the inoculum in the fast state 
(F0) was statistically significantly worse (dOFV  =  8.51; 
P < 0.005).
For strain MUSA, the MTP model with Gompertz growth 
function, constant transfer rates between the fast-multiplying 
and slow-multiplying states, and the inoculum estimated to 
be exclusively in the fast-multiplying state resulted in the best 
fit. Both a linear and logistic growth function decreased the 
fit substantially (∆AIC = 23.3 and 34.4, respectively). Model 
fit was very similar when parameterizing transfer between 
fast and slow states as capacity-dependent or time-depen-
dent, but based on precision of parameter estimates and 
parsimony, a constant transfer rate that requires less param-
eters, was selected for the final model. All tested approaches 
for the inoculum resulted in similar fits, based on parameter 
precision an inoculum in F0 was selected.
Figure 1 Natural growth of Mycobacterium marinum strains E11 (a) and MUSA (b) for hypoxic growth during 221 days. Previously 
published natural growth for Mycobacterium  tuberculosis12 (c) is included for comparison. Symbols: observed CFU/mL for the 
M. marinum strains. Lines: prediction of bacterial counts in fast-multiplying (black dashed line), slow-multiplying (dark grey dotted 
line), and non-multiplying (light grey dot-dashed line) states. The sum of fast-multiplying and slow-multiplying states (orange solid line) 
is assumed to equal colony forming unit (CFU)/mL.
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Final model predictions for number of bacteria in all 
three states as well as observed CFU/mL are shown in 
Figure 1a,b, final parameter estimates are given in Table 1, 
diagnostic plots are given in Supplementary Figures –S1–
S4. Model prediction of the three states for strain E11 shows 
relatively quick transfer from F to S and N, whereas for strain 
MUSA the F state is the major contributor to the total bac-
terial count. The growth rate constant of E11 and MUSA, 
0.188 and 0.169 day−1, respectively, was comparable to that 
of M.  tuberculosis (0.206  day−1).12 For M.  tuberculosis, S0 
was reported to contain the majority of the total inoculum,12 
which was similar to E11 but not MUSA.
DISCUSSION
To utilize M. marinum in the zebrafish tuberculosis disease 
model, quantification of its natural growth over an extended 
period is essential to study similarities and differences with 
M.  tuberculosis. We made a quantitative comparison be-
tween M. marinum strains and with M. tuberculosis using 
the established MTP model. This modeling and simulation 
approach is able to use the gained knowledge on potential 
differences when translating effects between species by in-
tegrating the quantified natural growth with the drug effects 
on the different states and translational factors correcting 
for between-species differences.15 A more parsimonious 
model with less compartments or parameters would result 
in similar predictions of CFU/mL for M. marinum, but would 
as a mere descriptive model lose its translational strength. 
The quantification of the natural growth of M. marinum in 
absence of therapeutic agents is the first step in the trans-
lational framework of the zebrafish as disease model for 
tuberculosis. A next step is to include drug effects on the 
different states of M. marinum in the model, similar to those 
already quantified on the different states of M. tuberculosis, 
with which it can be compared. A third step is the infec-
tion and treatment of zebrafish with M. marinum to quantify 
the drug effect within the context of a whole vertebrate, 
including an innate immune response. It is the advantage 
of the zebrafish as disease model with high-throughput 
potential to screen many different compounds, in contrast 
to infection experiments in higher vertebrates.25 Utilizing 
the MTP-based quantification of the M. marinum infec-
tion and treatment in the zebrafish will enable translation 
of the observations in this new model organism to higher 
vertebrates, including humans,15,16 an essential step in anti-
tuberculosis drug development.
Comparison of M. marinum to M. tuberculosis shows sim-
ilar growth rates, especially for strain E11, which also shows 
most similar model prediction for the bacterial counts in 
the three states (Figure c1), suggesting E11 to be prefera-
ble when studying tuberculosis pathology in zebrafish. The 
poikilotherm-derived E11 showed, with the prominence of 
the slow-multiplying state, a more latent growth behavior 
than the human-derived MUSA, which remained fast-multi-
plying for an extended period, suggesting more aggressive 
growth behavior. These characteristics are consistent with 
literature.19
In conclusion, the natural growth of M. marinum was char-
acterized and a quantitative comparison to M. tuberculosis 
was made using an established model-based approach. The 
improved understanding of the mycobacterial pathogen of 
the zebrafish tuberculosis disease model brings this prom-
ising and versatile model organism one step closer to the 
quantitative translational pipeline of antituberculosis drug 
development.
Table 1 Parameter estimates obtained with the final MTP model for natural growth of Mycobacterium marinum strain E11 and MUSA upon 














−1) 0.188 4.1 0.169 19.3 0.206
kFS (day
−1) 1.33a 25 0.0157a 9.5 0.00166a
Bmax (mL
−1) 4.99 × 1011 160 7.91 × 107 7.7 242 × 106
F0 (mL
−1) 0 FIX   8.51 × 105 21.2 4.1
S0 (mL
−1) 3.07 × 106 40.1 0 FIX   9,770
kFN (day
−1) 8.97 × 10−7 FIX   8.97 × 10−7 FIX   8.97 × 10−7
kSF (day
−1) 0.0145 FIX   0.0145 FIX   0.0145
kSN (day
−1) 0.186 FIX   0.186 FIX   0.186
kNS (day




0.227 9.5 0.205 9.5 0.407
Parameters reported for Mycobacterium tuberculosis with this model12 are depicted for comparison.
aBmax, maximum capacity of the system; F0, inoculum in the fast-multiplying state; kg, growth function, remaining k-values represent transfer rates from the 
state first mentioned in the subscript to the state mentioned second; MTP, multistate tuberculosis pharmacometric; S0, inoculum in the slow-multiplying 
state.
aM. marinum, transfer between fast-multiplying and slow-multiplying state was a constant function, for M. tuberculosis, transfer between fast-multiplying and 
slow-multiplying state was a time-dependent linear function (kFS = kFSlin ∙ time)
12 with unit day−2. 
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